Cell-Penetrating Peptide Delivers Anti-VEGF Eye Drug Without Injections | Research

The takeaway

An eye drop hydrogel using cell-penetrating peptides delivered aflibercept (an anti-VEGF drug) to treat corneal neovascularization, potentially replacing painful eye injections.

Eye drops replace injections
Cell-penetrating peptides enable topical anti-VEGF delivery through eye drops, eliminating the need for painful ocular injections

What the researchers found

Cell-penetrating peptide-mediated eye drop hydrogel successfully delivered aflibercept across the corneal barrier, reducing neovascularization without injection.

Why it matters

Eye injections are painful, carry infection risk, and require clinic visits. An eye drop that delivers the same anti-VEGF drugs using peptide technology could transform ophthalmic treatment and improve patient compliance.

The numbers in context

Gel 2_1&Eylea showed superior membrane permeability, increased stability, and prolonged drug contact time compared to standard formulations.

How the study worked

Developed CPP-aflibercept eye drop hydrogel formulation. Characterized corneal penetration and drug release. Tested efficacy in corneal neovascularization model.

Who was studied

Preclinical corneal neovascularization models treated with CPP-enhanced aflibercept eye drops

What this study cannot tell us

Preclinical study. Corneal drug delivery does not guarantee reaching the retina for diseases like macular degeneration. CPP-protein stability in eye drop formulations needs long-term evaluation.

How to read the evidence

Preliminary evidence: preclinical formulation study demonstrating CPP-enhanced corneal drug delivery. No human clinical data.

When this study was published

Published in 2024. Addresses a major unmet need in ophthalmic drug delivery.

The bigger picture

Cell-penetrating peptides are enabling non-invasive delivery of drugs that previously required injections. Eye drops represent one of the most patient-friendly applications — if CPPs can reliably deliver anti-VEGF drugs topically, it could expand treatment access for millions with eye diseases.

Questions still open

Could CPP-enhanced eye drops deliver anti-VEGF drugs deep enough for retinal diseases?
How does the efficacy of topical CPP-aflibercept compare to intravitreal injection?
What is the shelf life and stability of CPP-protein eye drop formulations?

Common questions

Could eye drops replace eye injections?

This study shows that cell-penetrating peptides can help large drug molecules cross the corneal barrier when delivered as eye drops. If this approach works in clinical trials, it could replace painful eye injections for conditions like corneal neovascularization.

What role do cell-penetrating peptides play?

The cornea normally blocks large molecules. CPPs act as molecular escorts that help the anti-VEGF drug aflibercept cross this barrier when applied as eye drops, achieving therapeutic drug levels without injection.

Read the original research

Aflibercept Loaded Eye-Drop Hydrogel Mediated with Cell-Penetrating Peptide for Corneal Neovascularization Treatment.

Small (Weinheim an der Bergstrasse, Germany), 20(2), e2302765

View on PubMed ↗Publisher’s paper ↗

Citation

Zhou, Jianan; Cai, Yuting; Li, Tingting; Zhou, Haixiang; Dong, Huilei; Wu, Xia; Li, Zenghui; Wang, Wenjie; Yuan, Dan; Li, Yun; Shi, Junfeng. (2024). Aflibercept Loaded Eye-Drop Hydrogel Mediated with Cell-Penetrating Peptide for Corneal Neovascularization Treatment.. Small (Weinheim an der Bergstrasse, Germany), 20(2), e2302765. https://doi.org/10.1002/smll.202302765